Effect of dutasteride on the expression of hypoxia-inducible factor-1α, vascular endothelial growth factor and microvessel density in rat and human prostate tissue

References

• Lekas E, Bergh A, Damber JE. Effects of finasteride and bicalutamide on prostatic blood flow in the rat. BJU Int. 2000;85:962–5.
   PubMed Web of Science ®Google Scholar
• Puchner PJ, Miller MI. The effects of finasteride on hematuria associated with benign prostatic hyperplasia: a preliminary report. J Urol. 1995;154:1779–82.
   PubMed Web of Science ®Google Scholar
• Carlin BI, Bodner DR, Spirnak JP, Resnick MI. Role of finasteride in the treatment of recurrent hematuria secondary to benign prostatic hyperplasia. Prostate. 1997;31:180–2.
   PubMed Web of Science ®Google Scholar
• Miller MI, Puchner PJ. Effects of finasteride on hematuria associated with benign prostatic hyperplasia: long-term follow-up. Urology. 1998;51:237–40.
   PubMed Web of Science ®Google Scholar
• Kashif KM, Foley SJ, Basketter V, Holmes SA. Haematuria associated with BPH – Natural history and a new treatment option. Prostate Cancer Prostatic Dis. 1998;1:154–6.
   PubMed Web of Science ®Google Scholar
• Sieber PR, Rommel FM, Huffnagle HW, Breslin JA, Agusta VE, Harpster LE. The treatment of gross hematuria secondary to prostatic bleeding with finasteride. J Urol. 1998;159:1232–3.
   PubMed Web of Science ®Google Scholar
• Foley SJ, Soloman LZ, Wedderburn AW, Kashif KM, Summerton D, Basketter V, A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Urol. 2000;163:496–8.
   PubMed Web of Science ®Google Scholar
• Kearney MC, Bingham JB, Bergland R, Meade-D’Alisera P, Puchner PJ. Clinical predictors in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasia. J Urol. 2002;167:2489–91.
   PubMed Web of Science ®Google Scholar
• Hagerty JA, Ginsberg PC, Harmon JD, Harkaway RC. Pretreatment with finasteride decreases perioperative bleeding associated with transurethal resection of the prostate. Urology. 2000;55:684–9.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Sharma H, Abraham R, Natalwala S. Thomas DR, Foster MC. Transurethral prostate resection and bleeding: a randomized, placebo controlled trial of the role of finasteride for decreasing operative blood loss. J Urol. 2002;168:2024–6.
   PubMed Web of Science ®Google Scholar
• Ozdal OL, Ozden C, Benli K, Gokkaya S, Bulut S, Memis A. Effect of short-term finasteride therapy on preoperative bleeding in patients who were candidates for transurethral resection of the prostate (TUR-P): a randomized controlled study. Prostate Cancer Prostatic Dis. 2005;8:215–8.
   PubMed Web of Science ®Google Scholar
• Crea G, Sanfilippo G, Anastasi G, Magno C, Vizzini C, Inferrera A. Pre-surgical finasteride therapy in patients treated endoscopically for benign prostatic hyperplasia. Urol Int. 2005;74:51–3.
   PubMed Web of Science ®Google Scholar
• Donohue JF, Hayne D, Karnik U, Thomas DR, Foster MC. Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks. BJU Int. 2005;96:1319–22.
   PubMed Web of Science ®Google Scholar
• Sandfeldt L, Bailey DM, Hahn RG. Blood loss during transurethral resection of the prostate after 3 months of treatment with finasteride. Urology. 2001;58:972–6.
   PubMed Web of Science ®Google Scholar
• Haggstrom S, Torring N, Moller K, Jensen E, Lund L, Nielsen JE, Effects of finasteride on vascular endothelial growth factor. Scand J Urol Nephrol. 2002;36:182–7.
   PubMed Web of Science ®Google Scholar
• Lund L, Moller Ernst-Jensen K, Torring N, Erik Nielsen J. Impact of finasteride treatment on perioperative bleeding before transurethral resection of the prostate: a prospective randomized study. Scand J Urol Nephrol. 2005;39:160–2.
   PubMed Web of Science ®Google Scholar
• Boccon-Gibod L, Valton M, Ibrahim H, Boccon-Gibod L, Commenducci A. Effect of dutasteride on reduction of intraoperative bleeding related to transurethral resection of the prostate. Prog Urol. 2005;15:1085–9.
   PubMed Web of Science ®Google Scholar
• Hahn RG, Fagerstrom T, Tammela TL, Van Vierssen Trip O, Beisland HP, Duggan A, Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride. BJU Int. 2007;99:587–94.
   PubMed Web of Science ®Google Scholar
• Levine AC, Liu XH, Greenberg PD, Eliashvili M, Schiff JD, Aaronson SA, Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology. 1998;139:4672–8.
   PubMed Web of Science ®Google Scholar
• Franck-Lissbrant I, Haggstrom S, Damber JE, Bergh A. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology. 1998;139:451–6.
   PubMed Web of Science ®Google Scholar
• Burchardt M, Burchardt T, Chen MW, Hayek OR, Knight C, Shabsigh A, Vascular endothelial growth factor-A expression in the rat ventral prostate gland and the early effects of castration. Prostate. 2000;15:184–94.
   Google Scholar
• Lekas E, Johansson M, Widmark A, Bergh A, Dmaber JE. Decrement of blood flow precedes the involution of the ventral prostate in the rat after castration. Urol Res. 1997;25:309–14.
   PubMedGoogle Scholar
• Hochberg DA, Basillote JB, Armenakas NA, Vasovic L, Shevchuk M, Pareek G, Decreased suburethral prostatic microvessel density in finasteride treated prostates: a possible mechanism for reduced bleeding in benign prostatic hyperplasia. J Urol. 2002;167:1731–3.
   PubMed Web of Science ®Google Scholar
• Pareek G, Shevchuk M, Armenakas NA, Vasjovic L, Hochberg DA, Basillote JB, The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density: a possible mechanism for decreased prostatic bleeding in treated patients. J Urol. 2003;169:20–3.
   PubMed Web of Science ®Google Scholar
• Lekas AG, Lazaris AC, Chrisofos M, Papatsoris AG, Lappas D, Patsouris E, Finasteride effects on hypoxia and angiogenetic markers in benign prostatic hyperplasia. Urology. 2006;68:436–41.
   PubMed Web of Science ®Google Scholar
• Park JW, Chun YS, Kim MS. Hypoxia-inducible factor 1-related diseases and prospective therapeutic tools. J Pharmacol Sci. 2004;94:221–32.
   PubMed Web of Science ®Google Scholar
• Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am J Pathol. 2000;157:411–21.
   PubMed Web of Science ®Google Scholar
• Du Z, Fujiyama C, Chen Y, Masaki Z. Expression of hypoxia-inducible factor 1α in human normal, benign, and malignant prostate tissue. Chin Med J. 2003;116:1936–9.
   PubMed Web of Science ®Google Scholar
• McConnell JD, Wilson JD, George FW, Geller J, Pappas F, Stoner E. Finasteride, an inhibitor of 4 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab. 1992;74:505–8.
   PubMed Web of Science ®Google Scholar
• Andriole GL, Humphrey P, Ray P, Gleave ME, Trachtenberg J, Thomas LN, Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. J Urol. 2004;172:915–9.
   PubMed Web of Science ®Google Scholar